9 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 10 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Recruiting 1, Terminated 1 |
| Phase 2 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
Follow Methoxydimethyltryptamines: new trials by email Literature Review of Methoxydimethyltryptamines trials Research Report on Methoxydimethyltryptamines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants 0.2 mg/min 5-MeO-DMT, 0.4 mg/min 5-MeO-DMT, 0.6 mg/min 5-MeO-DMT - 5-methoxy-dimethyltryptamine (5-MeO-DMT) | Phase 1 | Recruiting | University Hospital, Basel, Switzerland | 40 | 2026-08-13 | 2026-10-09 |
| Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects 5 Methoxy N,N Dimethyltryptamine, GH001 Aerosol Delivery System - Healthy Adult | Phase 1 | Completed | GH Research Ireland Limited | 13 | 2026-03-18 | 2026-10-07 |
| Trifecta Research Study Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment - PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction | Phase 2 | Withdrawn | Johns Hopkins University | 2025-09-01 | 2025-08-22 | |
| Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety BMND08, Brain electrical activity monitor, Pharmacokinetic Study of Sublingually Administered Psychoactive Substance - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Biomind Labs Inc. | 40 | 2024-10-21 | 2025-03-05 |
| Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects 5 Methoxy N,N Dimethyltryptamine - Healthy Volunteers | Phase 1 | Terminated | GH Research Ireland Limited | 71 | 2024-08-01 | 2026-10-09 |
| A Trial of GH001 in Patients With Treatment-resistant Depression GH001, Placebo - Treatment-resistant Depression | Phase 2 | Completed | GH Research Ireland Limited | 81 | 2023-05-24 | 2025-05-31 |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder GH001 - Bipolar II Disorder | Phase 2 | Terminated | GH Research Ireland Limited | 6 | 2023-04-06 | 2025-02-18 |
| Phase 2 Clinical Trial of GH001 in Postpartum Depression GH001 - Postpartum Depression, Postnatal Depression | Phase 2 | Terminated | GH Research Ireland Limited | 10 | 2023-03-02 | 2025-02-18 |
| Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers 5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo - Pharmacokinetics, Safety | Phase 1 | Completed | Usona Institute | 54 | 2022-12-27 | 2023-11-30 |
| Safety and Pharmacokinetics of GH002 in Healthy Volunteers 5 Methoxy N,N Dimethyltryptamine, Placebo - Healthy Volunteers | Phase 1 | Completed | GH Research Ireland Limited | 64 | 2022-12-22 | 2024-01-25 |
| Trifecta Research Study Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine - PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction | Active not recruiting | Axial Therapeutic Research | 52 | 2022-08-01 | 2026-07-21 | |
| Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects 5-MeO-DMT, Placebo - Pharmacokinetics in Healthy Adults | Phase 1 | Completed | Beckley Psytech Limited | 36 | 2021-09-22 | 2022-10-12 |
| Pharmacokinetics of GH001 in Healthy Volunteers 5 Methoxy N,N Dimethyltryptamine, Placebo - Healthy Volunteers | Phase 1 | Completed | GH Research Ireland Limited | 46 | 2021-06-21 | 2021-12-20 |
| Clinical Study of GH001 in Depression 5 Methoxy N,N Dimethyltryptamine - Treatment Resistant Depression, Major Depressive Disorder | Phase 1 / Phase 2 | Completed | GH Research Ireland Limited | 16 | 2019-11-12 | 2023-08-15 |
| Safety of GH001 in Healthy Volunteers 5 Methoxy N,N Dimethyltryptamine - Healthy Volunteers | Phase 1 | Completed | GH Research Ireland Limited | 22 | 2019-03-13 | 2023-08-15 |
Depression (6) · Brain Injuries (2) · Cognitive Dysfunction (2) · Combat Disorders (2) · Depressive Disorder, Major (2) · Depressive Disorder, Treatment-Resistant (2) · Stress Disorders, Post-Traumatic (2) · Anxiety Disorders (1) · Bipolar Disorder (1) · Brain Injuries, Traumatic (1) · Depression, Postpartum (1) · Mood Disorders (1) · Suicidal Ideation (1)
GH Research Ireland Limited (9) · Axial Therapeutic Research (1) · Beckley Psytech Limited (1) · Biomind Labs Inc. (1) · Johns Hopkins University (1) · University Hospital, Basel, Switzerland (1) · Usona Institute (1)
Netherlands (7) · United Kingdom (4) · United States (4) · Germany (2) · Argentina (1) · Czechia (1) · Ireland (1) · Poland (1) · Spain (1) · Switzerland (1)
I S Kroop (1) · Martin A. Bruno, PhD (1) · Sandeep Nayak, MD (1) · Severin Vogt, Dr. med. (1)
PMID 34912222, PMID 37409159, PMID 40659913, PMID 41879760, PMID 42247279
2018 (2), 2025 (1)